


(I)

either  $R_1$  is hydrogen or methyl and  $R_2$  is selected from the group consisting of cyclohexyl substituted by an amine,  $\text{CH}_2\text{CH}_2\text{NHCH}_3$ ,  $\text{CH}_2\text{CHCH}_3\text{NH}_2$ ,



$\text{CHCH}_3\text{CH}_2\text{NH}_2$ ,  $-(\text{CH}_2)_a\text{OH}$  where  $a$  is an integer of 1 to 8,  $(\text{CH}_2)_b-\text{C}\equiv\text{N}$  where

$b$  is an integer of 1 to 8,  $\text{CHCH}_3\text{C}_6\text{H}_5$ ,  $(\text{CH}_2)-\text{C}(\text{CH}_3)_2\text{NHCOCF}_3$ , and  $\text{CHCH}_3(\text{CH}_2)_d\text{OH}$  where  $d$  is an integer of 1 to 8

or  $R_1$  and  $R_2$  together with the nitrogen to which they are attached

form a ring of 3, 4 or 5 carbons optionally substituted by an amine  
R<sub>3</sub> is selected from the group consisting of hydrogen, methyl and  
hydroxyl

R<sub>4</sub> is hydrogen or hydroxyl,

R is selected from the group consisting of alkyl and cycloalkyl of  
up to 30 carbon atoms, optionally containing at least one  
heteroatom, at least one heterocycle and alkyl or cyclic acyl of up  
to 30 carbon atoms optionally containing at least one heteroatom,  
and/or at least one heterocycle,

T is selected from the group consisting of hydrogen, methyl,  
-CH<sub>2</sub>CONH<sub>2</sub>, -CH<sub>2</sub>C≡N, -(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub> and -(CH<sub>2</sub>)<sub>2</sub>Nalk<sup>+</sup>X<sup>-</sup>, X is halogen and alk  
is alkyl of up to 8 carbon atoms,

Y is selected from the group consisting of hydrogen, hydroxyl,  
halogen and -OSO<sub>3</sub>H or the salt thereof,

W is hydrogen or OH,

Z is hydrogen or methyl and its non-toxic, pharmaceutically  
acceptable acid addition salt.

Claim 2 (amended) A compound of claim 1 in which T is  
hydrogen.

Claim 3 (amended) A compound of claim 1 in which W is  
hydrogen.


Claim 4 (amended) A compound of claim 1 in which Z is  
methyl.







Claim 5 (amended) A compound of claim 1 in which Y is hydrogen.

Claim 6 (amended) A compound of claim 1 in which R<sub>3</sub> is methyl.


Claim 7 (amended) A compound of claim 1 in which R<sub>4</sub> is hydroxyl.

Claim 8 (amended) A compound of claim 1 in which R is selected from the group consisting of







and



Claim 9 (amended) A compound of claim 8 in which R is




Claim 10 (amended) A compound of claim 8 in which R is






Claim 11 (amended) A compound of claim 1 in which R<sub>1</sub> is hydrogen.


Claim 12 (amended) A compound of claim 1 in which R<sub>2</sub> is



Claim 13 A compound of claim 1 in which R<sub>2</sub> is selected from the group consisting of




Claim 14 (amended) A compound of claim 1 in which R2 is




Claim 15 (amended) A compound of claim 1 selected from the group consisting of

- 1-[4-[[ (1H-benzimidazol-2-yl)-methyl]-amino]-N2-[[4"-(pentyloxy)[1,1':4',1"-terphenyl]-4-yl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]5-L-serine-echinocandine B trifluoroacetate (isomer B), and
- trans 1-[4-[(2-aminocyclo-hexyl)-amino]-N2-[[4"-(pentyloxy)[1,1':4',1"-terphenyl]-4-yl-carbonyl]-L-ornithine]-4-[4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate (isomer A).

Claim 16 (amended) A process for the preparation of a compound of claim 1 comprising reacting a compound of the formula



wherein R, R<sub>3</sub>, R<sub>4</sub>, T, Y, W and Z are defined as in claim 1 with an amine or amine derivative capable of introducing



in which R<sub>1</sub> and R<sub>2</sub>

are defined as in claim 1 and optionally to the action of a reducing agent

and/or an amine functionalization agent,

and/or an acid to form the salt of the product of claim 1,

and/or a separation agent of the different isomers obtained.

Cancel claims 17 and 18 and add the following claims.